GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) » Definitions » Return-on-Tangible-Equity

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Return-on-Tangible-Equity : 12.21% (As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's annualized net income for the quarter that ended in Dec. 2024 was MAD61.9 Mil. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's average shareholder tangible equity for the quarter that ended in Dec. 2024 was MAD506.8 Mil. Therefore, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 was 12.21%.

The historical rank and industry rank for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Return-on-Tangible-Equity or its related term are showing as below:

CAS:PRO' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.16   Med: 17.38   Max: 29.17
Current: 11.18

During the past 9 years, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's highest Return-on-Tangible-Equity was 29.17%. The lowest was 11.16%. And the median was 17.38%.

CAS:PRO's Return-on-Tangible-Equity is ranked better than
64.34% of 903 companies
in the Drug Manufacturers industry
Industry Median: 6.67 vs CAS:PRO: 11.18

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Return-on-Tangible-Equity Historical Data

The historical data trend for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Return-on-Tangible-Equity Chart

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only 17.32 17.44 17.48 12.45 11.16

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.81 11.51 14.00 10.12 12.21

Competitive Comparison of PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Return-on-Tangible-Equity falls into.


;
;

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Return-on-Tangible-Equity Calculation

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=55.16/( (465.901+522.49 )/ 2 )
=55.16/494.1955
=11.16 %

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=61.886/( (491.139+522.49)/ 2 )
=61.886/506.8145
=12.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM  (CAS:PRO) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description

Traded in Other Exchanges
N/A
Address
Rue N 7, ZI du Sahel, BP 96/97, Berrechid, Had Soualem, MAR, 26400
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.